Cargando…
Immune Prognostic Factors in Ovarian Cancer: Lessons from Translational Research
Autores principales: | Gimotty, Phyllis A., Zhang, Lin, Alagkiozidis, Ioannis, Cadungog, Mark, Adams, Sarah, Chu, Christina, Katsaros, Dionysios, Coukos, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851646/ https://www.ncbi.nlm.nih.gov/pubmed/18057527 http://dx.doi.org/10.1155/2007/508350 |
Ejemplares similares
-
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer
por: Holtz, David O, et al.
Publicado: (2008) -
Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18
por: Alagkiozidis, Ioannis, et al.
Publicado: (2009) -
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
por: Alagkiozidis, Ioannis, et al.
Publicado: (2011) -
Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes
por: Adams, Sarah F, et al.
Publicado: (2020) -
Translational Research in Ovarian Cancer
por: Di Renzo, Maria Flavia, et al.
Publicado: (2020)